NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – September 12, 2024 Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreAgendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read More